Clinicopathological Features of Hereditary Nephritis in the Iranian Population: Analysis of a 14-Year Survey in Kidney Biopsies From a Large Referral Center

Overview

Journal Arch Iran Med

Specialty General Medicine

Date 2024 Mar 3

PMID 38431955

Authors

Amir Emami

Fatemeh Nili

Maryam Sotoudeh Anvari

Samaneh Salarvand

Golnar Seirafi

Affiliations

Soon will be listed here.

Abstract

Background: Hereditary nephritis (HN), including Alport syndrome (AS) and thin basement membrane nephropathy (TBMN), is a rare genetic cause of hematuria. A definitive diagnosis requires electron microscopy (EM). Therefore, the clinical characteristics of these conditions are less known. This study aimed to determine the percentage and clinicopathological features of HN in patients from a referral center in Iran.

Methods: We checked kidney biopsy reports from 2007 to 2021 and extracted cases with HN. Fresh specimens of the cases diagnosed in the last two years were stained by immunofluorescence (IF) for collagen type IV alpha chains. EM findings in these cases were re-evaluated and categorized as diffuse glomerular basement membrane (GBM) thinning, definite, and suspicious features of AS.

Results: We analyzed 3884 pathology reports of kidney biopsies from 2007 to 2021 and identified 210 patients (5.4%) with HN, with a mean age of 13.78±12.42 years old. Hematuria with proteinuria (53.3%), isolated hematuria (44.2%), and proteinuria with hematuria and increased creatinine (2.5%) were found in these patients. The re-evaluation of EM findings revealed GBM thinning, definite, and suspicious findings of AS in 37.5%, 43.8%, and 18.8% cases, respectively. The most common diagnosis in 32 cases after the IF study was X-linked AS (71.9%), and 6.2% of cases were autosomal recessive AS. TBMN and autosomal dominant AS remained the differential diagnoses in 21.9%.

Conclusion: It was found that EM is helpful for the primary diagnosis of patients with definite AS. Immunostaining improves the diagnostic sensitivity for the differentiation of those with suspicious EM findings and determines the inheritance pattern. However, a multidisciplinary approach for a subset of cases is required for the best diagnosis and management.

References

Matthaiou A, Poulli T, Deltas C . Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by or mutations: a systematic review. Clin Kidney J. 2021; 13(6):1025-1036. PMC: 7769542. DOI: 10.1093/ckj/sfz176. View

Savige J . Should We Diagnose Autosomal Dominant Alport Syndrome When There Is a Pathogenic Heterozygous or Variant?. Kidney Int Rep. 2018; 3(6):1239-1241. PMC: 6224634. DOI: 10.1016/j.ekir.2018.08.002. View

Pedrosa A, Bitencourt L, Paranhos R, Leitao C, Ferreira G, Simoes E Silva A . Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives. Curr Med Chem. 2021; 28(27):5602-5624. DOI: 10.2174/0929867328666210108113500. View

Wang Y, Rana K, Tonna S, Lin T, Sin L, Savige J . COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN). Kidney Int. 2004; 65(3):786-90. DOI: 10.1111/j.1523-1755.2004.00453.x. View

Yamamura T, Nozu K, Fu X, Nozu Y, Ye M, Shono A . Natural History and Genotype-Phenotype Correlation in Female X-Linked Alport Syndrome. Kidney Int Rep. 2017; 2(5):850-855. PMC: 5733817. DOI: 10.1016/j.ekir.2017.04.011. View

Nozu K, Nakanishi K, Abe Y, Udagawa T, Okada S, Okamoto T . A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol. 2018; 23(2):158-168. PMC: 6510800. DOI: 10.1007/s10157-018-1629-4. View

Kashtan C, Gross O . Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol. 2020; 36(3):711-719. DOI: 10.1007/s00467-020-04819-6. View

Senjug P, Nikuseva Martic T, Senjug Perica M, Oroz M, Horacek M, Jercic K . Clinical and pathohistological characteristics of Alport spectrum disorder caused by COL4A4 mutation c.193-2A>C: a case series. Croat Med J. 2021; 62(3):204-214. PMC: 8275942. View

Yao X, Chen X, Huang G, Yu Y, Xu S, Hu Y . Challenge in pathologic diagnosis of Alport syndrome: evidence from correction of previous misdiagnosis. Orphanet J Rare Dis. 2012; 7:100. PMC: 3552947. DOI: 10.1186/1750-1172-7-100. View

10.

Zurawski J, Burchardt P, Seget M, Moczko J, Wozniak A, Grochowalski M . Difficulties in differentiating thin basement membrane disease from Alport syndrome. Pol J Pathol. 2017; 67(4):357-363. DOI: 10.5114/pjp.2016.65869. View

11.

Jais J, Knebelmann B, Giatras I, Marchi M, Rizzoni G, Renieri A . X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol. 2000; 11(4):649-657. DOI: 10.1681/ASN.V114649. View

12.

Kajimoto Y, Endo Y, Terasaki M, Kunugi S, Igarashi T, Mii A . Pathologic glomerular characteristics and glomerular basement membrane alterations in biopsy-proven thin basement membrane nephropathy. Clin Exp Nephrol. 2019; 23(5):638-649. DOI: 10.1007/s10157-018-01687-1. View

13.

Kashtan C, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K . Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018; 93(5):1045-1051. DOI: 10.1016/j.kint.2017.12.018. View

14.

Lusco M, Fogo A . Hereditary Nephritis and Thin Glomerular Basement Membrane Lesion. Glomerular Dis. 2023; 1(3):135-144. PMC: 9677744. DOI: 10.1159/000516744. View

15.

Savige J, Colville D, Rheault M, Gear S, Lennon R, Lagas S . Alport Syndrome in Women and Girls. Clin J Am Soc Nephrol. 2016; 11(9):1713-1720. PMC: 5012472. DOI: 10.2215/CJN.00580116. View

16.

Savige J, Storey H, Watson E, Hertz J, Deltas C, Renieri A . Correction: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet. 2023; 32(1):132. PMC: 10772080. DOI: 10.1038/s41431-023-01288-x. View

17.

Haas M . Alport syndrome and thin glomerular basement membrane nephropathy: a practical approach to diagnosis. Arch Pathol Lab Med. 2009; 133(2):224-32. DOI: 10.5858/133.2.224. View

18.

Li A, Gao E, Cui Y, Liu J, Lv X, Wei X . Three Novel Heterozygous COL4A4 Mutations Result in Three Different Collagen Type IV Kidney Disease Phenotypes. Cytogenet Genome Res. 2018; 154(1):30-36. DOI: 10.1159/000486979. View

19.

Savige J, Lipska-Zietkiewicz B, Watson E, Hertz J, Deltas C, Mari F . Guidelines for Genetic Testing and Management of Alport Syndrome. Clin J Am Soc Nephrol. 2021; 17(1):143-154. PMC: 8763160. DOI: 10.2215/CJN.04230321. View

20.

Zhang Y, Bockhaus J, Wang F, Wang S, Rubel D, Gross O . Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr Nephrol. 2021; 36(9):2719-2730. PMC: 8370956. DOI: 10.1007/s00467-021-05040-9. View